GlyTherix is a leading immuno-oncology company that specializes in cancer therapeutics. With a strong focus on improving patient outcomes, GlyTherix possesses a comprehensive intellectual property portfolio for the treatment of solid tumors. Their innovative approach involves targeting Glypican-1 (GPC-1), a protein overexpressed in various types of cancers including prostate, pancreatic, bladder, glioblastoma, esophageal, lung, and ovarian cancers.

One of GlyTherix's notable achievements includes the completion of a successful First-in-Human trial using their groundbreaking antibody, Miltuximab®. This antibody has shown promising results without any drug-related adverse events observed in the trial's 12 patients. Currently, GlyTherix is actively raising funds for a Phase-1b theranostic study to expand the evaluation of Miltuximab®.

Additionally, GlyTherix is developing a humanized version of Miltuximab® called Glytuzumab®, which is currently undergoing Lead Optimization and Lead Selection. The company has generated several leads with similar binding affinities to Miltuximab®, and the selected lead will be further developed for future clinical trials. GlyTherix's commitment to advancing cancer therapeutics is further evidenced by their collaborations, achievements, and partnerships with prominent organizations such as ANSTO, Adcendo, GEMINI, and Carina Biotech.

For investors, potential partners, or individuals who want to learn more about GlyTherix's groundbreaking work and how they can contribute to better cancer therapeutics, detailed information is available on their website. Overall, GlyTherix stands at the forefront of immuno-oncology, harnessing scientific advancements to revolutionize cancer treatment and improve patient outcomes